Pegloticase

Drug Index

Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated.[1] The drug is administered by infusion intravenously. It was developed by Savient Pharmaceuticals.[2][3] It was approved in the United States in 2010, after two clinical trials found it lowered uric acid levels and reduced deposits of uric acid cryst...

Pegloticase

Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated.[1] The drug is administered by infusion intravenously. It was developed by Savient Pharmaceuticals.[2][3] It was approved in the United States in 2010, after two clinical trials found it lowered uric acid levels and reduced deposits of uric acid cryst...

sir can you send me full article of same to below mentioned email

NDC Database

Krystexxa 8 mg/ml Intravenous Injection, Solution by Horizon Pharma Inc. ## Package Codes: 75987-080-10 ## Active Ingredients: Pegloticase

NDC Database

Krystexxa 8 mg/ml Intravenous Injection, Solution by Crealta Pharmaceuticals LLC ## Package Codes: 60809-801-01 ## Active Ingredients: Pegloticase

NDC Database

Krystexxa 8 mg/ml Intravenous Injection, Solution by Savient Pharmaceuticals, Inc. ## Package Codes: 54396-801-01 ## Active Ingredients: Pegloticase